Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC.
KSQ Therapeutics Inc., in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), have announced FDA clearance of an IND application for a phase I/II study of KSQ-001EX, KSQ’s lead engineered tumor-infiltrating lymphocyte (eTIL) program.
Carisma Therapeutics Inc. has received FDA clearance of its IND application for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor (CAR)-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).
Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.
Why cancer? The mechanisms that drive and maintain tumorigenesis are still a mystery. This is a play with different actors who have different roles in several contexts. One of these scenarios is represented by genetic and epigenetic conditions that determine the early trajectories of cancer cells. In addition, different mechanisms will control phenotypes and states that can take one or another direction toward cancer.
Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.
Medigene AG has announced a prioritization of its pipeline as it advances its differentiated T-cell receptor engineered T cell (TCR-T) therapies for solid tumors.
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has finalized the protocol for a preclinical dose-ranging efficacy study of VTX-0P4, a protein-based cancer vaccine targeting prostate stem cell antigen (PSCA), a key target in the treatment of prostate cancer.